AliveCor is a Mountain View, California based company founded in 2010 that is dedicated to transforming cardiological care through the use of deep learning. The company's flagship product, the KardiaMobile device, is an FDA-cleared personal ECG solution that is highly clinically-validated. Through their latest innovation, KardiaMobile 6L, AliveCor has achieved instant detection of various heart conditions like Atrial Fibrillation, Bradycardia, and Tachycardia using deep learning. The company is also the first to introduce AI-enabled technology aiding both patients and clinicians in the efficient detection of atrial fibrillation, a condition associated with high stroke risk. Moreover, AliveCor offers an advanced enterprise platform allowing third-party providers to manage their patients' and customers' heart conditions effectively with the use of state-of-the-art tools. What sets AliveCor apart is its commitment to customer data security and compliance, evident through its achievements of ISO 27001 Certification, SOC 2 Type 2 Certification, and HIPAA compliance attestation. The company also offers consumer-level ECG devices for direct sale, enhancing accessibility to essential cardiac care. With the mission of saving lives and transforming cardiology at its core, AliveCor's innovation and dedication to excellence make it a promising prospect for potential investors. As a privately-held company, its continuous advancements in the field and commitment to data security make it an attractive opportunity for venture capital funding. For more information, visit alivecor.com.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series F | Unknown | 6 | 16 Aug 2022 | |
Series E | $65.00M | 5 | Omron Healthcare | 16 Nov 2020 |
Venture Round | $5.78M | - | 22 Oct 2019 | |
Private Equity Round | Unknown | - | 10 Oct 2019 | |
Debt Financing | $20.00M | 1 | Oxford Finance LLC | 29 Jan 2019 |
No recent news or press coverage available for AliveCor.